A Phase 3 interventional study of Vonaprument in Geographic Atrophy, sponsored by Annexon, Inc.. Not yet recruiting at 7 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-09-08.
Sponsored by Annexon, Inc. · Phase 3, Interventional, and Treatment
The primary purpose of the study is to assess the long term safety of intravitreal (IVT) injections of vonaprument.
Exclusion Criteria:
Participants will receive vonaprument IVT injections every month for 24 months.
Drug: Vonaprument
Form: solution for injection; Route of Administration: IVT injection
Also known as: ANX007
Number of Participants with Treatment Emergent Adverse Events
Time frame: Through Month 24
Plan to share: No
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Annexon, Inc.